Skye Bioscience (SKYE) Interest Coverage Ratio (2012 - 2026)
Skye Bioscience (SKYE) posted quarterly Interest Coverage Ratio of 5763.7 for Q1 2026, up 28.83% year-over-year from 4473.76 in Q1 2025, and down 75612.24% quarter-over-quarter from 7.61 in Q3 2025.
Skye Bioscience (SKYE) Interest Coverage Ratio (2012 - 2026) Analysis & Trends
Skye Bioscience (SKYE) has reported Interest Coverage Ratio for 15 consecutive years, with 5763.7 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Coverage Ratio rose 28.83% year-over-year to 5763.7; the TTM figure through Mar 2026 stood at 164.46 (up 235.34% YoY), while the FY2024 annual figure was 0.45, up 14.72% from the prior year.
- Interest Coverage Ratio eased to 5763.7 in Q1 2026 per SKYE's latest filing, from 7.61 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 54.74 in Q3 2024 and bottomed at 8098.87 in Q1 2025.
- Historically, Interest Coverage Ratio has averaged 882.47 across 5 years, with a median of 13.94 in 2022.
- Annual changes were most pronounced in 2023 — Interest Coverage Ratio jumped 204.72% — and 2025, when it plunged 747445.66%.
- Skye Bioscience's Interest Coverage Ratio stood at 14.05 in 2022, then surged by 204.72% to 14.71 in 2023, then surged by 99.81% to 29.39 in 2024, then sank by 125.9% to 7.61 in 2025, then plunged by 75612.24% to 5763.7 in 2026.
- Business Quant data shows SKYE's Interest Coverage Ratio at 5763.7 in Q1 2026, 7.61 in Q3 2025, and 8.78 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 2.82 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.08 |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.42 |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 76.86 |
| 10 | Skye Bioscience | 11.17 Mn | 11.17 Mn | - | -3,352.93 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5,763.70 |
| Sep 30, 2025 | -7.61 |
| Jun 30, 2025 | -8.78 |
| Mar 31, 2025 | -8,098.87 |
| Dec 31, 2024 | 29.39 |
| Sep 30, 2024 | 54.74 |
| Jun 30, 2024 | -5.49 |
| Mar 31, 2024 | -1.08 |
| Dec 31, 2023 | 14.71 |
| Sep 30, 2023 | -91.06 |
| Jun 30, 2023 | -15.25 |
| Mar 31, 2023 | -168.52 |
| Dec 31, 2022 | -14.05 |
| Sep 30, 2022 | -13.83 |
| Jun 30, 2022 | -15.68 |
| Mar 31, 2022 | -14.51 |
| Dec 31, 2021 | -12.38 |
| Sep 30, 2021 | -9.31 |
| Jun 30, 2021 | -9.63 |
| Mar 31, 2021 | -9.40 |